IHS Chemical Week

Regions :: North America :: U.S.

Lonza and BioWa sign licensing agreement with AstraZeneca

3:53 AM MST | December 11, 2013 | Deepti Ramesh

Lonza and BioWa (La Jolla, CA), a wholly owned subsidiary of biopharmaceutical company Kyowa Hakko Kirin (Tokyo), have entered into a licensing agreement with MedImmune (Gaithersburg, MD), the global biologics R&D arm of AstraZeneca (London). MedImmune has licensed the companies’ Potelligent CHOK1SV cell line technology for use in multiple proprietary antibodies in its pipeline. MedImmune entered into a previous licensing agreement with BioWa in 2007 for Potelligent technology. Today’s agreement incorporates Lonza’s technology to the...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa